Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 May;38(3):251-259.
doi: 10.1007/s40290-024-00524-z. Epub 2024 May 6.

Trends in Adverse Event Reporting Before and After the Introduction of the Med Safety App in Nigeria

Affiliations
Observational Study

Trends in Adverse Event Reporting Before and After the Introduction of the Med Safety App in Nigeria

Uchenna Geraldine Elemuwa et al. Pharmaceut Med. 2024 May.

Abstract

Introduction: Spontaneous reporting of adverse events (AEs) is a mainstay of pharmacovigilance, and an ongoing challenge is how to ensure that more high-quality reports are collected for comprehensive information provision. The Med Safety App, a smartphone-based application, was launched in Nigeria in November 2020 to provide an electronic platform for users to seamlessly report AEs. There has been a paucity of evidence on the use of this application or other mobile applications for reporting adverse drug reactions/AEs following immunization in the Nigerian environment.

Objective: The aim of this study was to evaluate the trends in adverse event reporting before and after the introduction of the Med Safety App in Nigeria.

Methods: This was a retrospective, observational study using data from the VigiFlow database to compare adverse event reporting in Nigeria before and after the deployment of the Med Safety App. The baseline period was 1st April 2019 to 30th October 2020 and the comparison period was 1st November 2020 to 31st May 2022. We used Vigilance Hub, the back-end system for the Med Safety App, to extract data on App downloads and de-identified user statistics. Data were summarized using descriptive statistics, frequencies and proportions. Quality was assessed by assigning a completeness score to each individual case safety report. The Kruskal-Wallis test was used to test for differences in medians between groups.

Results: Following deployment of the App, the Nigerian National Pharmacovigilance Centre recorded an increase in the total number of adverse event reports received in VigiFlow, from 2051 in the baseline period to 18,995 following deployment of the App, with 81.7% of those reported via the Med Safety App. There was a reduction in the proportion of paper-based reporting from 98.4 to 15.7% post-deployment, and direct reporting by consumers increased from 2.7 to 17.6%. Of the 15,526 reports submitted via the App, 15,111 (97.3%) had a completeness score above 70% and 6993 (45%) had a completeness score of 100%. The median completeness score of adverse event reports on the Med Safety App was 6 out of 7. On bivariate analysis using the Kruskal-Wallis test, there was an association between means of reporting and completeness score, and this association was significant, with a p value of 0.0001, which may reflect the validation rules that are applied within the App.

Conclusion: Deployment of the Med Safety App increased both the number and quality of adverse event reports; however, more awareness and capacity building are needed to strengthen and sustain reporting on the tool by all categories of healthcare professionals and consumers/patients.

PubMed Disclaimer

References

    1. World Health Organization. Safety of medicines. A guide to detecting and reporting adverse drug reactions (WHO/EDM/QSM/2002.2). Geneva: World Health Organization; 2002.
    1. Federal Ministry of Health. Nigerian National Pharmacovigilance Policy and Implementation Framework. 2020. https://msh.org/wp-content/uploads/2021/03/nigerian_national_pharmacogil... . Accessed 10 July 2023.
    1. World Health Organization. WHO pharmacovigilance indicators: a practical manual for the assessment of pharmacovigilance systems (ISBN 9789241508254). https://apps.who.int/iris/bitstream/handle/10665/186642/9789241508254_en... . Accessed 10 July 2023.
    1. Fukushima A, Iessa N, Balakrishnan MR, et al. Smartphone-based mobile applications for adverse drug reactions reporting: global status and country experience. BMC Med Inform Decis Mak. 2022;22(1):118. https://doi.org/10.1186/s12911-022-01832-7 . - DOI - PubMed - PMC
    1. Gahr M, Eller J, Connemann BJ, et al. Underreporting of adverse drug reactions: results from a survey among physicians. Eur Psychiatry. 2017;2017(41 Suppl):S369. https://doi.org/10.1016/j.eurpsy.2017.02.377 . - DOI

Publication types

MeSH terms

LinkOut - more resources